www.feizichem.com   Shijiazhuang FeiZi Chemical Technology Co., Ltd.

Driven by green transition and high‑quality development, China’s chemical industry is undergoing accelerated restructuring. High‑value‑added niche sectors such as pharmaceutical intermediates and fine chemicals have become major growth bright spots. According to customs statistics, China’s export value of active pharmaceutical ingredients (APIs) and intermediates reached USD 23.44 billion in the first half of 2026, rising by 5.9 % year‑on‑year, while export volume increased by 11.1 % year‑on‑year, notably outperforming the full‑year growth rate for 2025. Industry analyses indicate that the market share of conventional generic intermediates is gradually declining. High‑value‑added intermediates for innovative drugs and complex formulations have emerged as the core engine driving market expansion. Against this backdrop, Shijiazhuang Feizi Chemical Technology Co., Ltd., a specialist in pharmaceutical intermediates, is forging deeper into niche markets with its flagship product 1-(2-Methoxyphenyl)piperazine hydrochloride (CAS: 5464-78-8).

 1. A Fine‑Chemical Enterprise in Shijiazhuang Focused on Pharmaceutical Intermediates

Founded in 2022, Shijiazhuang Feizi Chemical Technology Co., Ltd. specializes in the R&D, production and sales of pharmaceutical intermediates and fine‑chemical products. Its manufacturing plant is located in Shijiazhuang Circular Chemical Industrial Park, covering an area of about 50 mu with more than 60 employees. The company’s portfolio comprises nearly one‑hundred products across urea, sulfonic acid, pyrimidine, piperazine and naphthalene‑based intermediate series, widely applied in pharmaceuticals, agrochemicals, dyes, surfactants and personal‑care sectors. Its management team draws core talent from listed pharmaceutical companies, and operations comply with the ISO 9001 quality‑management system.

 2. 1‑(2‑Methoxyphenyl)piperazine hydrochloride

Featured in this release is 1-(2-Methoxyphenyl)piperazine hydrochloride (CAS: 5464-78-8), one of the company’s core offerings. As a piperazine‑class pharmaceutical intermediate, it serves as a key building‑block for synthesizing the classic antihypertensive drug Urapidil. It is also used in the preparation of Naftopidil and for multiple organic‑synthesis workflows.

Urapidil hydrochloride is a selective α₁‑adrenoceptor antagonist with central 5‑HT₁ₐ receptor‑agonist activity. As a non‑catecholamine antihypertensive agent, it is widely used clinically for blood‑pressure reduction in hypertensive emergencies and peri‑operative hypertension. With deepening population ageing and growing demand for hypertension management in China, consumption volumes for cardiovascular medicines including Urapidil remain steady. Accordingly, requirements for purity, single‑impurity control and batch‑to‑batch consistency for its upstream intermediates keep rising. Such products feature high technical barriers and cannot compete purely on low prices.

For this product, Feizi Chemical implements full‑process quality control covering synthesis, purification, drying and packaging to guarantee consistent quality across batches. Supporting documentation including specification recommendations, Material Safety Data Sheets (MSDS) and Certificates of Analysis (COA) are available for customers.

 3. Compliance and Quality: Upholding Standards amid Industry Value‑Driven Competition

Notably, current industry policies are creating tangible benefits for enterprises focusing on R&D and quality. A representative from Feizi Chemical states that the company has long followed the business logic of “setting costs based on quality and setting prices based on costs”. It avoids cut‑throat low‑price competition and instead invests R&D and quality‑control capabilities into high‑value‑added key intermediates.

Meanwhile, regulations governing precursor chemicals for narcotics and explosive‑prone chemicals impose mandatory requirements for enterprise qualifications, accounting records and product‑flow traceability. Feizi Chemical sticks to compliant business practices, improves filing for purchases and sales as well as inventory record‑keeping for incoming and outgoing goods. It only transacts with formal enterprises and laboratory clients and supplies complete MSDS and COA documents, delivering reliable and traceable chemical raw‑materials for downstream pharmaceutical manufacturers, new‑material producers and research institutions.

 4. Outlook: Evolving from Intermediate Supplier to Comprehensive‑Solution Provider

Industry observers note that leading intermediate manufacturers equipped with green synthesis and continuous‑production capabilities can secure long‑term supply orders via technical barriers. Feizi Chemical states it will further increase R&D investment and optimize manufacturing processes. Leveraging existing R&D and production capacity, the firm will expand into more high‑value‑added nitrogen‑containing heterocyclic compounds and piperazine derivatives. It aims to transform from a single‑product supplier into a comprehensive‑solution provider and contribute to the high‑end and green upgrading of China’s fine‑chemical industrial chain.